Never miss an update from Biogen. Did you know that during reporting season, the announcements from NASDAQ:BIIB often move the market?
|52w High/Low:||$236.26 - 355.63|
|Volume/Average:||156K - 3M|
They're dirt cheap compared to their peers. David Jagielski The price at which you buy a stock can greatly affect your overall returns. While you don't necessarily want to wait forever for a stock to fall to a price where you think it's cheap enou...3 Best Biotech Stocks to Buy in November
While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease. Jason Hawthorne Often, the best investments are the ones most ...Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals?
Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates? Jim Halley Shares in Biogen (NASDAQ:BIIB) were ...Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy
This biotech titan should be a top player on the merger and acquisition scene next year. George Budwell Biogen (NASDAQ:BIIB) might be in deep trouble. The biotech's core multiple sclerosis franchise has been hit hard by generic competition this ye...Why Warren Buffett's Riskiest Bet in Years Is on the Brink of Bombing
The odds appear to be heavily against this Berkshire investment paying off. Keith Speights Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.Warren Buffett isn't exactly viewed as a big gambler. Sure, the Oracle of ...Every Stock Tells a Story
Beyond numbers. Motley Fool Staff In this episode of Rule Breaker Investing, Motley Fool co-founder David Gardner is joined by Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers, to share stories about some interesting stocks and how t...Why Biogen Stock Is Tanking Today
The biotech's high-profile Alzheimer's disease drug candidate appears to be headed for a rejection. George Budwell Biotech heavyweight Biogen (NASDAQ:BIIB) saw its shares sink by as much as 32% in pre-market trading Monday. The biotech's stock is ...FDA Committee Votes Strongly Against Biogen's Alzheimer's Disease Drug
The committee of outside experts saw right through the FDA's cheerleading. Brian Orelli, PhD After a long day of the Food and Drug Administration and Biogen (NASDAQ:BIIB) arguing that Biogen's Alzheimer's disease drug, aducanumab, should be approv...